Up to 150,000 people in England are set to benefit from treatment with AstraZeneca's Forxiga (dapagliflozin), after the health technology assessment institute, NICE, recommended making the drug available via the National Health Service to treat adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.
Forxiga is the first treatment for this patient population to be recommended by NICE. The recommendation was issued on 18 May in the form of a final draft guidance,...
Key Takeaways
-
Forxiga is the first treatment that NICE has recommended for treating adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction....